Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe keloid tissue for clues to stop overgrown scars

NCT ID NCT07682636

Knowledge-focused Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study looks at keloid scars—raised, overgrown scars that can be itchy or painful—to understand why they form. Researchers will compare keloid tissue with normal skin from the same person, using lab tests to spot key molecules that drive scar growth. The goal is to uncover new targets for future treatments, not to test a therapy itself.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If key molecular drivers are identified, this could point toward new drug targets for preventing or reducing keloid scarring.
What could go wrong
This is a small observational study, not a treatment trial. Findings may not translate into effective therapies, and laboratory results may not reflect real-world biology.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with clinically diagnosed keloids who are scheduled to undergo surgical excision at The Fourth Affiliated Hospital, Zhejiang University School of Medicine. Residual keloid tissue and adjacent normal skin tissue obtained during routine surgery will be used for laboratory analysis after written informed consent.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinically diagnosed with keloid. * Age 18 years or older. * Scheduled to undergo surgical treatment at the study hospital. * Able and willing to provide written informed consent. Exclusion Criteria: * Severe systemic disease. * History of neurologic disease, alcoholism, postherpetic neuralgia, HIV infection, hypothyroidism, diabetes mellitus, or prior cancer chemotherapy. * Other skin diseases within 5 cm of the keloid lesion, such as eczema. * Systemic treatment within 7 days before enrollment or keloid-specific treatment within 6 weeks before enrollment, including intralesional corticosteroid injection, cryotherapy, topical medication, or silicone gel sheeting. * Hormone or immunosuppressive therapy within 3 months before enrollment. * Pregnancy or breastfeeding. * Considered unsuitable for participation by the investigator. * Refusal to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fibroblast are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

keloid

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fibroblast Keloids

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Fourth Affiliated Hospital of Zhejiang University School of Medicine

    RECRUITING

    Jinhua, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.